CytRx

CytRx’s Aldoxorubicin shows improved QoL in chemotherapy resistant cancers

Monday, May 4, 2015

CytRx, a biopharmaceutical R&D company specializing in oncology, has announced an interim analysis from its two ongoing phase Ib aldoxorubicin combination studies pairing aldoxorubicin with either gemcitabine or ifosfamide. Both studies combine standard doses of gemcitabine or ifosfamide with escalating doses of aldoxorubicin. The combinations appear to be well-tolerated, and even at the lowest dose level of aldoxorubicin (170mg/m2), impressive tumor responses have been observed so far in patients with bone cancer (osteosarcoma) and a variety of soft tissue sarcomas. As such, aldoxorubicin has the potential when used in combination with other cancer agents to become an important new weapon against chemotherapy resistant cancers.

[Read More]

Dr. Anita J. Chawla joins CytRx board of directors

Thursday, March 12, 2015

CytRx, a biopharmaceutical R&D company specializing in oncology, has appointed Anita J. Chawla, Ph.D., to its board of directors. Chawla brings over 25 years of experience as an economist in the health care industry to CytRx, with a proven track record helping pharmaceutical, biotechnology, medical device and diagnostic companies achieve their product development and commercialization objectives.

[Read More]

CytRx announces partial clinical hold affecting aldoxorubicin clinical trials

Monday, November 24, 2014

CytRx, a biopharmaceutical R&D company specializing in oncology, has received notice from the FDA that its clinical trials for aldoxorubicin have been placed on partial clinical hold. All currently enrolled patients can continue receiving aldoxorubicin treatment, or comparator drugs, as per study protocols, but no new patients can be enrolled until the clinical hold is lifted.

[Read More]

CytRx launches discovery laboratory to develop anti-cancer drug platform

Thursday, October 16, 2014

CytRx, a Los Angeles-Calif.-based biopharmaceutical R&D company specializing in oncology, has commenced operations at its new discovery laboratory in Freiburg, Germany. The new laboratory will conduct discovery and translational research to create drug candidates that utilize novel linker technologies that couple chemotherapeutic agents and proteins either inside the body or externally, and then concentrate drug in tumors.

[Read More]

CytRx receives multiple FDA Orphan Drug designations for Aldoxorubicin

Thursday, October 2, 2014

CytRx, a biopharmaceutical R&D company specializing in oncology, has announced that the FDA has granted multiple Orphan Drug designations for the company’s lead drug candidate, aldoxorubicin, in three indications: glioblastoma multiforme (GBM), small cell lung cancer and ovarian cancer. Aldoxorubicin is CytRx’s modified version of the widely-used chemotherapeutic agent, doxorubicin.

[Read More]